Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Cerus multi-layered sales growth trajectory 'convincing,' says Cowen » 14:07
08/10/20
08/10
14:07
08/10/20
14:07
CERS

Cerus

$7.13 /

+0.08 (+1.13%)

Cowen analyst Joshua…

Cowen analyst Joshua Jennings says that Cerus multi-year multi-layered sales growth trajectory is "convincing." The American Red Cross' commitment to transition to 100% INTERCEPT Platelets alone could drive 15%-20%-plus top line growth in 2021/2022, he contends. Further, the analyst notes that numerous growth opportunities are also "evolving nicely" including the non-ARC U.S. platelet opportunity, the German platelet market, INTERCEPT Cryo, and INTERCEPT RBCs. Jennings reiterates an Outperform rating on the shares, with a $9.50 price target on the stock.

ShowHide Related Items >><<
CERS Cerus
$7.13 /

+0.08 (+1.13%)

CERS Cerus
$7.13 /

+0.08 (+1.13%)

06/16/20 Cantor Fitzgerald
Cerus assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
Cerus assumed with an Overweight at Cantor Fitzgerald
05/26/20 Stifel
Cerus price target raised to $8 from $7 at Stifel
02/26/20 BTIG
Cerus initiated with a Buy at BTIG
CERS Cerus
$7.13 /

+0.08 (+1.13%)

  • 29
    Jan
CERS Cerus
$7.13 /

+0.08 (+1.13%)

Hot Stocks
Aspen Group reports 2,351 new student enrollments in Q1 » 09:16
08/10/20
08/10
09:16
08/10/20
09:16
ASPU

Aspen Group

$11.01 /

+0.54 (+5.16%)

Aspen Group announced a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASPU Aspen Group
$11.01 /

+0.54 (+5.16%)

ASPU Aspen Group
$11.01 /

+0.54 (+5.16%)

07/14/20
Fly Intel: Top five analyst initiations
07/14/20 B. Riley FBR
B. Riley FBR starts 'innovative' Aspen Group with Buy, $14 target
07/14/20 B. Riley FBR
Aspen Group initiated with a Buy at B. Riley FBR
06/03/20 Lake Street
Aspen Group price target raised to $14 from $11 at Lake Street
ASPU Aspen Group
$11.01 /

+0.54 (+5.16%)

  • 17
    Jan
  • 13
    Dec
ASPU Aspen Group
$11.01 /

+0.54 (+5.16%)

Recommendations
Survey indicates strengthening recovery in Apple iPhone sales, says KeyBanc » 07:02
08/10/20
08/10
07:02
08/10/20
07:02
AAPL

Apple

$444.41 /

-10.98 (-2.41%)

, AVGO

Broadcom

$325.77 /

-3.39 (-1.03%)

, QCOM

Qualcomm

$108.26 /

-2.72 (-2.45%)

, SWKS

Skyworks

$143.85 /

-3.58 (-2.43%)

, SYNA

Synaptics

$88.96 /

-0.8 (-0.89%)

KeyBanc analyst John Vinh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SYNA Synaptics
$88.96 /

-0.8 (-0.89%)

SWKS Skyworks
$143.85 /

-3.58 (-2.43%)

QCOM Qualcomm
$108.26 /

-2.72 (-2.45%)

AVGO Broadcom
$325.77 /

-3.39 (-1.03%)

AAPL Apple
$444.41 /

-10.98 (-2.41%)

AAPL Apple
$444.41 /

-10.98 (-2.41%)

08/06/20 KeyBanc
Synaptics upgraded to Overweight from Sector Weight at KeyBanc
08/06/20 Barclays
SiTime price target raised to $75 from $50 at Barclays
08/05/20
Fly Intel: Top five analyst downgrades
08/05/20 Wells Fargo
Apple price target raised to $485 from $450 at Wells Fargo
AVGO Broadcom
$325.77 /

-3.39 (-1.03%)

07/13/20 KeyBanc
Data indicates 'strong recovery' in Apple iPhone sales, says KeyBanc
07/08/20 Rosenblatt
Synaptics upgraded to Buy on acquisition accretion at Rosenblatt
07/06/20 Goldman Sachs
Broadcom price target raised to $322 from $286 at Goldman Sachs
QCOM Qualcomm
$108.26 /

-2.72 (-2.45%)

08/03/20 Bernstein
Qualcomm upgraded to Outperform at Bernstein
08/03/20 Bernstein
Qualcomm upgraded to Outperform from Market Perform at Bernstein
07/31/20
Fly Intel: Top five analyst upgrades
07/31/20 Edward Jones
Qualcomm upgraded to Hold on Huawei settlement at Edward Jones
SWKS Skyworks
$143.85 /

-3.58 (-2.43%)

08/03/20 Standpoint Research
Skyworks downgraded to Hold from Buy at Standpoint Research
07/24/20 B. Riley FBR
Skyworks price target raised to $170 from $165 at B. Riley FBR
07/24/20 Craig-Hallum
Skyworks price target raised to $150 from $120 at Craig-Hallum
07/24/20 Baird
Skyworks price target raised to $145 from $125 at Baird
SYNA Synaptics
$88.96 /

-0.8 (-0.89%)

08/06/20 Needham
Synaptics price target raised to $120 from $100 at Needham
08/06/20 BMO Capital
Synaptics price target raised to $90 from $70 at BMO Capital
08/06/20 Mizuho
Synaptics price target raised to $90 from $77 at Mizuho
SYNA Synaptics
$88.96 /

-0.8 (-0.89%)

SWKS Skyworks
$143.85 /

-3.58 (-2.43%)

QCOM Qualcomm
$108.26 /

-2.72 (-2.45%)

AVGO Broadcom
$325.77 /

-3.39 (-1.03%)

AAPL Apple
$444.41 /

-10.98 (-2.41%)

QCOM Qualcomm
$108.26 /

-2.72 (-2.45%)

AVGO Broadcom
$325.77 /

-3.39 (-1.03%)

AAPL Apple
$444.41 /

-10.98 (-2.41%)

SYNA Synaptics
$88.96 /

-0.8 (-0.89%)

SWKS Skyworks
$143.85 /

-3.58 (-2.43%)

QCOM Qualcomm
$108.26 /

-2.72 (-2.45%)

AVGO Broadcom
$325.77 /

-3.39 (-1.03%)

AAPL Apple
$444.41 /

-10.98 (-2.41%)

SWKS Skyworks
$143.85 /

-3.58 (-2.43%)

QCOM Qualcomm
$108.26 /

-2.72 (-2.45%)

AVGO Broadcom
$325.77 /

-3.39 (-1.03%)

AAPL Apple
$444.41 /

-10.98 (-2.41%)

AAPL Apple
$444.41 /

-10.98 (-2.41%)

Friday
Hot Stocks
Aclaris continues to pursue strategic alternatives, including seeking partners » 07:24
08/07/20
08/07
07:24
08/07/20
07:24
ACRS

Aclaris Therapeutics

$1.95 /

-0.22 (-10.14%)

Aclaris continues to…

Aclaris continues to pursue strategic alternatives, including seeking partners for: A-101 45% Topical Solution: to obtain regulatory approval and commercialize A-101 45% Topical Solution, an investigational compound, as a potential treatment for common warts; ATI-501 & ATI-502: to further develop, obtain regulatory approval and commercialize ATI-501 and ATI-502, investigational JAK 1/3 inhibitor compounds, as potential treatments for alopecia; and ESKATA: to commercialize ESKATA topical solution, 40%.

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

Hot Stocks
Aclaris Therapeutics to submit IND for ATI-2138 in 2021 » 07:23
08/07/20
08/07
07:23
08/07/20
07:23
ACRS

Aclaris Therapeutics

$1.95 /

-0.22 (-10.14%)

Aclaris is developing…

Aclaris is developing ATI-2138 as a potential treatment for psoriasis and/or inflammatory bowel disease and expects to submit an IND for ATI-2138 in 2021.

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

Hot Stocks
Aclaris Therapeutics to initiate Phase 1/2a trial of ATI-1777 in 2H20 » 07:22
08/07/20
08/07
07:22
08/07/20
07:22
ACRS

Aclaris Therapeutics

$1.95 /

-0.22 (-10.14%)

ATI-1777-AD-201: Aclaris…

ATI-1777-AD-201: Aclaris expects to initiate a Phase 1/2a multicenter, randomized, double-blind, vehicle-controlled trial to investigate the safety, tolerability, pharmacokinetics and efficacy of topically applied ATI-1777 in subjects with moderate to severe AD in the second half of 2020. The primary endpoint will assess efficacy at four weeks.

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

Hot Stocks
Aclaris Therapeutics to progress to first-in-human trial of ATI-1777 » 07:22
08/07/20
08/07
07:22
08/07/20
07:22
ACRS

Aclaris Therapeutics

$1.95 /

-0.22 (-10.14%)

Aclaris submitted an…

Aclaris submitted an Investigational New Drug Application for ATI-1777 for the treatment of moderate to severe atopic dermatitis in June 2020 and now plans to progress to the first-in-human trial of ATI-1777 in subjects with moderate to severe AD.

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

Hot Stocks
Aclaris Therapeutics expects to initiate ATI-450-CAPS-201 trial in 2H20 » 07:21
08/07/20
08/07
07:21
08/07/20
07:21
ACRS

Aclaris Therapeutics

$1.95 /

-0.22 (-10.14%)

ATI-450-CAPS-201: Aclaris…

ATI-450-CAPS-201: Aclaris expects to initiate a Phase 2a clinical trial of ATI-450 in cryopyrin-associated periodic syndrome, an IL1beta-driven disease, in the second half of 2020.

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

Hot Stocks
Aclaris Therapeutics sees data from ATI-450-RA-201 trial in 1H21 » 07:20
08/07/20
08/07
07:20
08/07/20
07:20
ACRS

Aclaris Therapeutics

$1.95 /

-0.22 (-10.14%)

ATI-450-RA-201: An…

ATI-450-RA-201: An ongoing Phase 2a trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis. This trial was initiated in March 2020. Due to the COVID-19 pandemic, Aclaris temporarily paused enrollment. Aclaris resumed enrolling subjects, and the first subject was dosed, in May 2020. At this time, Aclaris is actively recruiting for this trial. Given the continuing evolution of the COVID-19 pandemic, Aclaris now anticipates reporting data from this trial in the first half of 2021.

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

Hot Stocks
Aclaris Therapeutics expects cash to be sufficient through 1Q22 » 07:05
08/07/20
08/07
07:05
08/07/20
07:05
ACRS

Aclaris Therapeutics

$1.95 /

-0.22 (-10.14%)

Aclaris anticipates that…

Aclaris anticipates that its cash, cash equivalents and marketable securities as of June 30, 2020 will be sufficient to fund its operations through the first quarter of 2022, without giving effect to any potential business development transactions or financing activities.

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

ACRS Aclaris Therapeutics
$1.95 /

-0.22 (-10.14%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.